New Gout Medication Approved in China; Phase III Results Announced for US Cancer Vaccine

On August 20, 2026, China’s National Medical Products Administration (NMPA) approved the Class 1 innovative drug anfilimab injection (subcutaneous injection, brand name Yisaina), developed by Sunland Guojian Pharmaceutical (Shanghai) Co., Ltd. The new drug is indicated for acute gouty arthritis in adults who have contraindications to, intolerance of, or inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and/or colchicine, and for whom repeated use of corticosteroids is inappropriate. This approval provides a new, targeted treatment option for patients with clinically refractory acute gout.

Gout is a highly prevalent chronic metabolic disease in China, caused by long-term elevated uric acid levels in the blood. Acute attacks are characterized by severe joint pain, redness, and swelling, significantly impairing patients’ quality of life. For a long time, first-line clinical treatments have primarily relied on NSAIDs, colchicine, and corticosteroids. However, for patients with concurrent liver or kidney dysfunction, underlying gastrointestinal diseases, or frequent attacks, traditional therapies have clear limitations, leaving an unmet clinical need.

Anfilimab is a recombinant humanized anti-IL-1β monoclonal antibody. By specifically targeting and blocking IL-1β, the core inflammatory mediator in acute gout attacks, it suppresses the inflammatory cascade at its source. With its precise mechanism of action, the drug is specifically designed for patient populations with limited conventional treatment options, further expanding the clinical toolkit for the acute phase of gout.

In recent years, China has been at the forefront of innovative gout drug development globally. In 2025, fosimimab, a novel IL-1β-targeting drug developed by GeneScience Pharmaceuticals, was approved for market. Earlier this year, Hengrui Medicine’s next-generation uric acid-lowering drug, a URAT1 inhibitor, luzunole sodium, also received marketing approval.

On August 19, 2026, a personalized vaccine co-developed by US pharmaceutical companies Moderna and Merck was shown to reduce melanoma recurrence rates in a large-scale, late-stage clinical trial, raising hopes for treating this most deadly form of skin cancer.

According to a joint statement from the two companies, combining the vaccine with Merck’s immunotherapy drug Keytruda is more effective at preventing cancer recurrence after surgical removal and delaying the spread of cancer cells to other parts of the body than using immunotherapy alone. It is reported that over 1,000 melanoma patients participated in this mRNA cancer therapy trial. The vaccine could potentially receive regulatory approval as early as 2027.

While this is welcome news for cancer patients, some oncology experts urge caution regarding this breakthrough, as the full study results have not yet been published or peer-reviewed; the findings have currently only been disclosed by the developing companies.

In cancer research, similar sensational announcements are not uncommon, but subsequent results often fall short of expectations. Therefore, maintaining a cautious and watchful stance toward these findings is appropriate.

New achievements in drug development are always encouraging. Many human diseases require innovative pharmaceutical solutions, and researchers on the front lines of drug discovery have made significant contributions to improving human health. We look forward to more breakthrough successes in the future.